Plaintiffs Build Case Against Diabetes Drug
“In the wake of a new study linking the Type II diabetes drug Avandia to a 43 percent increase in the risk of a heart attack, the plaintiffs' bar is building its failure-to-warn case against GlaxoSmithKline, the drug's manufacturer. Although no personal injury suits had been filed at press time, a shareholder class action was filed on behalf of investors, claiming that GlaxoSmithKline issued multiple ‘false and misleading’ statements about the drug. Meanwhile, personal injury lawyers have been fielding a steady stream of calls since the study came out. Both Thomas Kline of Kline & Specter in Philadelphia and Karen Barth Menzies of Baum Hedlund in Los Angeles are currently evaluating cases. The potential for litigation is vast, because more than a million people have taken the drug in the U.S. alone - and 6 million worldwide. Like Vioxx, the major claims by Avandia plaintiffs will be failure-to-warn and aggressive marketing despite risks the drug maker knew or should have known existed.”
Reni Gertner, Lawyers USA 6/19/07
http://www.lawyersusaonline.com/subscriber/archives.cfm?page=usa/07/618071.htm
Bookmark: 
